Clinical Trials Logo

Clinical Trial Summary

The primary objective was to compare progression-free survival in adults with relapsed multiple myeloma who are receiving CRd vs participants receiving Rd in a randomized multicenter setting.


Clinical Trial Description

This is a Phase 3, randomized, open-label, multicenter study comparing two treatment regimens for adults with relapsed multiple myeloma. Eligible subjects will be randomized in a 1:1 ratio to receive either the control Rd or CRd. Randomization will be stratified by β2 microglobulin levels (< vs ≥ 2.5 mg/L), prior bortezomib (no vs yes), and prior lenalidomide (no vs yes). Participants will receive the treatment determined by randomization in 28-day cycles until disease progression or unacceptable toxicity (whichever occurs first). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01080391
Study type Interventional
Source Amgen
Contact
Status Completed
Phase Phase 3
Start date July 14, 2010
Completion date December 5, 2017

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04083534 - First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) Phase 1/Phase 2
Recruiting NCT06119685 - IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers Phase 1/Phase 2
Recruiting NCT05577000 - Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT01118689 - Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia Phase 1
Withdrawn NCT04802031 - Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma Phase 2
Completed NCT02401295 - ATRA, Celecoxib, and Itraconazole as Maintenance Phase 1
Active, not recruiting NCT00603447 - Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma Phase 1
Active, not recruiting NCT02722668 - UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Phase 2
Active, not recruiting NCT04965155 - A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone) Phase 2
Completed NCT00592579 - A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma Phase 2
Recruiting NCT06304636 - Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma Phase 1
Completed NCT03158688 - Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. Phase 3
Completed NCT04434469 - A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma Phase 1
Not yet recruiting NCT06348108 - Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT01949532 - Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease Phase 1
Active, not recruiting NCT04398485 - A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma Phase 1
Recruiting NCT03091933 - Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) Phase 1/Phase 2
Completed NCT01272466 - Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma Phase 1/Phase 2
Recruiting NCT05896228 - Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma Phase 2
Terminated NCT04119336 - Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma Phase 2